Haploinsufficient P14 CD8+ T cells— presumably with about half the normal level of TOX protein— controlled B16-gp33 tumor growth better than wildtype P14 cells (10), and bulk RNA-seq data showed that there was residual Tox mRNA on day 8 after transfer in the shTOX-treated CAR TILs that were effective in controlling tumor growth (8). This evidence concerns the gene CD8A and neoplasm.